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ing by ElAbstract Crhon’s disease is a life-long chronic relapsing condition. Morbidity is high and its inci-
dence and prevalence are increasing worldwide. The purpose of this work is to determine whether
magnetic resonance imaging can be used to categorize small bowel Crhon’s disease into groups that
correlate with response to medical therapy.
Twenty-ﬁve patients (10 males and 15 females) age range (13–80 years) who had an established
diagnosis of Crhon’s disease were subjected to magnetic resonance imaging to categorize small
bowel Crhon’s disease into groups and to correlate these groups with response to medical therapy.
Patients without luminal narrowing were more likely to respond to medical therapy (P< 0.0001)
than patients with luminal narrowing and hold up (P= 0.007).
Patients with mild or marked small bowel intestinal wall enhancement were more likely to respond
(P< 0.0001) than those with small bowel abnormalities without enhancement. Our ﬁndings would
support the use of small bowel MRI as a diagnostic and prognostic tool in the management of
patients with small bowel Crhon’s disease.
 2011 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
All rights reserved.(O.A. Kamal).
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Crhon’s disease is a life-long chronic relapsing condition.
Morbidity is high and its incidence andprevalence are increasing
worldwide (1). Despite the development of new medical thera-
pies, there is little evidence that they alter the natural history
of Crhon’s disease. Due to the transmural nature of Crhon’s
disease, ﬁbrosis, stenosis and obstruction often result (2).
Crhon’s disease frequently involves the terminal ileum so,
investigation of the small bowel is of utmost importance.
Unfortunately, terminal ileum assessment by endoscopy is
not optimal, with a signiﬁcant proportion of colonoscopic
336 O.A. Kamal, M.M. Shabrawyexaminations failing to reach the cecum (3). The mainstay of
small bowel investigation has been small bowel enterography
or small bowel enteroclysis that requires placement of a nas-
ojejunal tube. More recently, CT enteroclysis, wireless capsule
enteroscopy, double balloon enteroscopy, magnetic resonance
small bowel enteroclysis and magnetic resonance enterography
have become available. Conventional radiology only has a sen-
sitivity of between 23% and 80% for the detection of typical
Crhon’s disease radiological lesion (4–6). It delivers ionizing
radiation and is suboptimal for the assessment of extraintesti-
nal involvement and complications. Wireless capsule enteros-
copy on the other hand allows for optimal visualization of
the small bowel mucosa but its speciﬁcity is lower than other
methods (6). It does not clearly localize the lesions, histological
studies cannot be performed, and there is a small but deﬁnite
capsule retention rate contraindicating its use in small bowel
strictures (7).
CT enteroclysis has been well described, has good sensitiv-
ity (71–95%) and impressive speciﬁcity (90–98%) and is supe-
rior to conventional enteroclysis (8,9). The use of ionizing
radiation in CT enteroclysis in a generally young patient co-
hort, however, is not ideal. CT enteroclysis also lacks func-
tional information, has poor ﬂuoroscopic control of small
bowel ﬁlling and suboptimal soft tissue contrast (6,10,11).
Magnetic resonance has the potential to overcome these
limitations. It is characterized by a very high soft tissue con-
trast, lack of ionizing radiation and lower incidence of adverse
events related to the intravenous contrast employed compared
with CT (12). MRI also has high sensitivity and speciﬁcity in
the evaluation of Crhon’s disease (13) and while it does not
provide as consistently good mucosal detail as conventional
enteroclysis, it has a strong correlation with pathologic ﬁnd-
ings and does not use ionizing radiation (14,15). MRI also
demonstrates good soft tissue contrast, subtle degrees of con-
trast enhancement and conveys functional information while
potentially differentiating active inﬂammation from ﬁbrosis
in preliminary studies (16,17). The purpose of this work is to
determine whether magnetic resonance imaging (MRI) can
be used to categorize small bowel Crhon’s disease (SBCD) into
groups that correlate with response to medical therapy.2. Materials and methods
Twenty-ﬁve patients (10 males and 15 females), age range (13–
40 years) mean age (25.5 years) were referred by the gastroen-
terologist to Radiology Department for Magnetic Resonance
Imaging. All patients had an established diagnosis of Crhon’s
disease on previous endoscopic examination with histological
conﬁrmation of at least 6 months duration had on going clin-
ical symptoms of activity. All patients were subsequently sub-
jected to magnetic resonance imaging to categorize small
bowel Crhon’s disease into groups and to correlate these
groups with response to medical therapy.
3. MRI preparation
All patients drink only ﬂuids for 6 hours prior to MRI . They
all underwent MR enterography and drink 1000 ml of biphasic
bowel contrast agent for 20 minutes. The bowel contrast agent
used was polyethylene glycol – water solution (Glycoprep C,
pharmatel Fresenius Kabi, Australia).4. MRI technique
Patients were imaged supine using a 1.5 T MRI system (Avan-
to SQ) with a surface array coil providing compression.
A scout image was done to insure adequate coverage. Small
bowel ﬁlling was assessed using a coronal 150 mm thick single
slabT2weighted (HASTE) for saturated sequence taken repeated
without breath holding for monitoring stomach ﬁlling and small
bowel distension. T1 and T2W images with or without fat satu-
ration were also obtained in coronal and axial planes.
To reducebowel peristalsis andprolong small bowel distension,
10 mg intravenous Buscopan was given if there were no contrain-
dications. Once there was adequate small bowel ﬁlling, a coronal
precontrast T1 weighted 3D gradient echo (VIBE) with a 2 mm
slice thickness was obtained. Intravenous omniscan was injected
(0.2 ml/kg) with post contrast imaging commencing at 60 s. Post
contrast sequences (T1 W images with or without fat saturation
and VIBE images) were obtained in coronal and axial planes.
Further imaging included axial and coronal steady state
free precession sequences (True FISP) with a 6 mm slice thick-
ness with and without fat saturation, coronal T2 weighted half
fourier singleshot turbospin echo (HASTE) sequence with
6 mm thickness and axial T2 weighted HASTE sequence with
5 mm slice thickness.
5. MRI classiﬁcation
Based on the small bowel MRI ﬁndings, the Crhon’s disease
patients, were categorized into ‘‘4’’ categories: (1) Fibrosis,
(2) Mild segmental hyperenhancement and mild wall thicken-
ing. (3) Mild segmental hyperenhancement and marked wall
thickening (4) Marked segmental transmural hyperenhance-
ment (Table 1).
Diseased bowel was identiﬁed as abnormal bowel wall
thickness (Figs. 1–7) and abnormal transmural (Figs. 6
and 7) or mucosal enhancement (Fig. 5). Bowel wall thickness
was assessed as normal (<3 mm), mildly abnormal (3–6 mm)
or markedly abnormal (>6 mm) (18).
Mucosal enhancement was contrast enhancement localized
to the inner layer of the intestinal wall. Transmural enhance-
ment was homogenous contrast enhancement of the whole wall.
The degree of pathological bowel wall contrast enhance-
ment was assessed as none, mild (less than renal cortical
enhancement) or marked (more than renal cortical enhance-
ment) and classiﬁed as mucosal, transmural or both. Studies
were classiﬁed as ‘‘ﬁbrosis’’ if there was bowel wall thickening
without contrast enhancement. The diagnostic conﬁdence of
this was increased if the wall thickening had reduced signal
intensity on T1 and T2 weighted images and if this region
remained of constant caliber.
Marked segmental transmural hyperenhancement was
diagnosed if there was marked transmural enhancement with
increased bowel wall thickness. Mild segmental hyper enhance-
ment and mild wall thickening were present if mucosal and/or
transmural contrast enhancement was mild with only mild bo-
wel wall thickening (3–6 mm). Mild segmental hyper enhance-
ment and marked wall thickening were present if there was
mild mucosal and/or transmural contrast enhancement but
the bowel wall was >6 mm. Deep ulcerations are seen as
linear, high signal intensity protrusions into the bowel wall
(Figs. 2 and 3) (19).
Table 1 Grouping by MRI ﬁndings.
Category 1 Category 2 Category 3 Category 4
Mucosal enhancement Nil Mild Mild Mild or marked
Transmural enhancement Nil Nil or mild Nil or mild Marked
Wall thickness (mm) >3 <6 >6 >6
Figure 1 Bowel wall thickening (arrow). An abnormal thickness is >3 mm.
Figure 2 Mucosal hyperemia, engorged ileal vasa recta (comb sign) (arrowhead), deep ulcers (double arrows), bowel wall thickening
(curved arrow) and small mesenteric lymph nodes (notched arrow). Note separation of bowel loops due to fat proliferation of the
mesentery.
Figure 3 Bowel wall thickening and deep ulceration (notched arrow). An ulcer has traversed the bowel and an early ﬁstulation (arrow) is
visible.
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Figure 4 Mural thickening of caecal apex with inﬂammatory pseudomass (arrow) formation.
Figure 5 Bowel wall thickening (arrowhead), a stricture (arrow), proximal dilation, mucosal enhancement (curved arrow); enhancement
localized to inner layer of bowel wall.
Figure 6 Bowel wall thickening (arrow). Transmural enhancement (double arrows); enhancement of the entire bowel wall without
stratiﬁcation.
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Figure 7 Bowel wall thickening (arrows). Transmural enhancement (curved arrows).
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cal lymph nodes (Fig. 2) and/or abnormally enhancing lymph
nodes were assessed. Mesenteric nodes >5 mm in short axis
were considered physiological. Larger nodes especially if clus-
tered and contrast enhancing were considered pathological (20).
Disease complications including ﬁstulas (Fig. 3), abscesses,
inﬂammatory masses (Fig. 4), sinuses and strictures (Fig. 5)
were recorded.
6. Response to medical therapy
Response and remission and continued medical therapy were
assessed by the Harvey Bradshaw index (HBI) (21).
A response was a reduction in the HBI of P 3 and remis-
sion was deﬁned as HBI of <5. A response was determined
after a further 8 weeks of medical therapy. Correlation be-
tween the MRI ﬁndings and response to medical therapy was
assessed.
7. Results
Twenty-ﬁve patients (10 males and 15 females), age range
(13–80 years) mean age (45.5 years) were referred by the
gastroenterologist to Radiology Department for magnetic
resonance imaging. All patients had an established diagnosis
of Crhon’s disease on previous endoscopic examination with
histological conﬁrmation of at least 6 months duration had
ongoing clinical symptoms of activity. All patients were subse-
quently subjected to magnetic resonance imaging to categorize
small bowel Crhon’s disease into groups and to correlate these
groups with response to medical therapy.
16 patients (64%) had disease conﬁned to the small bowel
and 9 patients (36%) suffered from ileocolonic disease.
Utilizing a combination of the maximal small bowel wall
thickness and level of mucosal/mural enhancement, patients
were allocated into 1 of 4 categories (Table 1).
All the patients in category ‘‘4’’ also show 2 or more extra-
intestinal changes of inﬂammation (i.e. mesenteric hyperemia,
ﬁbrofatty proliferation, enlarged regional lymph nodes, patho-
logical lymph node enhancement or free ﬂuid) indicating a
more severe level of inﬂammation.MRI detection of bowel wall enhancement and its degree,
level of bowel wall thickness, as well as the presence of an ab-
scess, ﬁbrofatty proliferation, mesenteric hyperemia, a ﬁstula,
free ﬂuid or enlarged regional lymph nodes are detailed in
Table 2). The length of bowel involved and the presence of
luminal narrowing with or without prestenotic dilatation,
patient age and sex are also presented.
The medical therapies received by the patients included the
use of steroids, antibiotics and anti – TNF alphatherapy. Med-
ical therapy was not standardized between patients but was tai-
lored to the individual patient.
Five patients (20%) of the 25 patients failed to respond to
medical therapy (4 patients with small bowel Crhon’s disease
and 1 patient with ileocolonic disease). The average HBI was
8.7 (range 6–20) prior to medical therapy. Statistical analysis
identiﬁed that females were more likely to respond to medical
therapy than males. Patients without luminal narrowing were
more likely to respond to medical therapy (P< 0.0001) than
patients with luminal narrowing and hold up (P= 0.007).
Luminal narrowing was observed in 62.5%, 66.6% and
75% of patients in category ‘‘2’’, ‘‘3’’ and ‘‘4’’, respectively,
while narrowing also occurred in 85.7% of patients in category
‘‘1’’ suggesting that luminal narrowing can occur without the
presence of inﬂammation detected by MRI.
Patients with mild or marked small bowel intestinal wall
enhancement were more likely to respond (P< 0.0001) than
those with small bowel abnormalities without enhancement.
Patients with intestinal narrowing and prestenotic dilata-
tion with or without hold up were less likely to respond to
medical therapy (P= 0.008)
Luminal narrowing and presterotic dilatation with or with-
out hold up was abserved in 14.3%, 0%, 16.6% and 25% of
patients in category ‘‘1’’, ‘‘2’’, ‘‘3’’ and ‘‘4’’, respectively.
No signiﬁcant differences were detected between response
rates and age, the presence of mesenteric hyperemia, ﬁbrofatty
proliferation, enlarged local lymph nodes, nodal enhancement,
free ﬂuid, length of involved segment or the presence of ﬁstulas
or an abscess. MRI ﬁndings of marked wall thickening without
wall enhancement were observed to be less likely to respond to
medical therapy, while minimal bowel wall thickening with
mild wall enhancement shows good response to continued
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340 O.A. Kamal, M.M. Shabrawymedical therapy. There was no difference in patient response
related to enhancement localized to the mucosal or mural lay-
ers compared to enhancement in both layers.
8. Discussion
Crhon’s disease is a chronic inﬂammatory disease of the gas-
trointestinal tract that is characterized by ulceration, strictures
and ﬁstula formation. Crhon’s disease commonly affects
young adults and typically runs a chronic relapsing and remit-
ting course.
The indolent nature of the disease leads to frequent imaging
examinations for monitoring disease activity and severity in or-
der to guide appropriate treatment. The use of immune mod-
ulating drugs has increased the need for accurate assessment
of the activity and severity of disease.
Cross – sectional imaging investigations such as computed
tomography (CT) and magnetic resonance imaging (MRI)
are particularly suited to assess the macroscopic features,
extramural abnormalities and complications. The high tissue
contrast obtained using MRI coupled with the absence of ion-
izing radiation makes it ideally suited for imaging patients with
Crhon’s disease. (22). The good soft tissue contrast may differ-
entiate between intestinal inﬂammation and ﬁbrosis and
appears to be superior to CT scanning (16,17).
As Crhon’s disease is a transmural disease it may result in
obstructive symptoms secondary to intestinal inﬂammation
and/or ﬁbrosis. Fibrosis is not effectively treated by pharma-
ceutical agents and the presence of ﬁbrotic strictures is one rea-
son behind the high rate of surgical intervention (23). Overall
imaging techniques (US, MRI, CT or scintigraphy) have high
per patient sensitivity (84.3–93%) and speciﬁcity (84.5–95.6%)
for the diagnosis of inﬂammatory bowel disease.
CT is widely used in CD yet it carries a high radiation bur-
den and the results of a recent metanalysis conclude that it is
preferable to use a non ionizing technique such as US or
MRI in CD (23).
A recent study has highlighted the high cumulative radia-
tion dosages imported to patients with CD mainly due to the
increased use of CT. The carcinogenic effect of radiation can
be particularly signiﬁcant in patients with CD who already
have an increased risk of developing gastrointestinal cancer
and small bowel lymphoma (24).
Several scientiﬁc reports have reported that the inherent tis-
sue contrast resolution obtained on MRI can provide good
mural and extramural details. Although as yet there is not en-
ough evidence that MRI can identify early mucosal ulcers,
some studies have shown that MRI has a good correlation
with barium enteroclysis in demonstration of mucosal lesions.
(25). MRI studies have reported sensitivities and speciﬁcities
ranging between 88–98% and 78–100%, respectively, in the
detection of CD (26).
In our study we were able to identify early ulcers as deep
depression in mucosal surface or areas of low T1 and high
T2 signal intensity causing disruption in the mucosal layer.
Deep ulcers were identiﬁed as being extended into the submu-
cosal layer. Comparison with barium enteroclysis was beyond
the scope of our study.
The cardinal principle behind obtaining diagnostic small
bowel images is good distension and opaciﬁcation of the bowel
lumen coupled with ultrafast MRI sequences and intravenous
contrast. Distension of the small bowel can be achieved with
Prognostic role of MRI in determining small bowel Crhon’s disease categories: 341intubation (MR enteroclysis) or non intubation (MR enterog-
raphy) techniques. The intubation technique can provide de-
tailed luminal information yet its advantages have been
counter balanced by the complexity of the procedure, patient
discomfort and the need for sedation (27).
The non intubation technique is another technique where a
large volume of oral contrast medium is ingested by the patient
prior to imaging. In our study we use this technique, it is less
complex, less uncomfortable for the patient, it produces good
opaciﬁcation of bowel although it may not be optimal and uni-
form as compared with the enteroclysis examination (27).
There are limited studies that compare MRI ﬁndings with
small bowel inﬂammation, but they suggest that contrast
enhancement intensity correlates with intestinal inﬂammation.
MRI data that combines both bowel wall thickening and sig-
nal intensity has previously demonstrated greater accuracy in
assessing disease severity (28).
In view of these observations patients in our study were
classiﬁed according to intestinal wall enhancement and bowel
wall thickening on MRI.
Our ﬁndings suggest that the small bowel MRI ﬁndings can
be used to categorize CD patients and that these categories
correlate with patient response to ongoing medical therapy.
No signiﬁcant differences were detected between the medi-
cal therapy regime used and the response/remission rates over-
all, or between any of the MRI categories suggesting that the
medical therapy was not primarily responsible for differences
observed in the response rates.
In our study females were more likely to respond to medical
therapy than males. The reason behind this was unclear but
may be attributed to that in our study sample, females were
more than males (60%:40%)
In our study patients without luminal narrowing were more
likely to respond to medical therapy (P< 0.0001) than pa-
tients with luminal narrowing and hold up (P= 0.007). These
ﬁndings were in agreement with Craig et al. (29) in their study
done on 2009, they categorized CD patients according to MRI
ﬁndings and correlated these categories with patient response
to ongoing medical therapy.
In our study, patients with mild or marked small bowel
intestinal wall enhancement were more likely to respond
(P< 0.0001) than those with small bowel abnormalities with-
out enhancement.
Patients with intestinal narrowing and prestenotic dilata-
tion with or without hold up were less likely to respond to
medical therapy (P= 0.008). This fully agreed with Craig
et al. (29).
A further ﬁnding of their work in full agreement with our
ﬁndings is that no signiﬁcant differences were detected between
response rates and age, the presence of mesenteric hyperemia,
ﬁbrofatty proliferation, enlarged local lymph nodes, nodal
enhancement, free ﬂuid, length of involved segment or the
presence of ﬁstulas or an abscess.
In agreement with Craig et al. (29) we also found that MRI
ﬁndings of marked wall thickening without wall enhancement
were observed to be negatively associated with a response to
medical therapy, while minimal bowel wall thickening with
mild wall enhancement predicted a good response to continued
medical therapy.
Lastly, both studies found that there was no difference in pa-
tients response related to enhancement localized to the mucosal
or mural layers compared to enhancement in both layers.9. Conclusion
As patient categories by MRI based on small bowel wall thick-
ness and wall enhancement appear to correlate with the re-
sponse to continuing medical therapy, our ﬁndings would
support the use of small bowel MRI as a diagnostic and prog-
nostic tool in the management of patients with small bowel
Crhon’s disease.
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